[HTML][HTML] A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
Y Zhou, H Zong, L Han, Y Xie, H Jiang, J Gilly… - Journal of Experimental …, 2020 - Springer
Background Prolactin receptor (PRLR) is highly expressed in a subset of human breast
cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical …
cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical …
Rapid development of stable transgene CHO cell lines by CRISPR/Cas9-mediated site-specific integration into C12orf35
M Zhao, J Wang, M Luo, H Luo, M Zhao, L Han… - Applied microbiology …, 2018 - Springer
Chinese hamster ovary (CHO) cells are the most widely used mammalian hosts for
recombinant protein production. However, by conventional random integration strategy …
recombinant protein production. However, by conventional random integration strategy …
[HTML][HTML] Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system
L Han, J Chen, K Ding, H Zong, Y Xie, H Jiang… - Scientific Reports, 2017 - nature.com
Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial
application. However, huge challenges still remain in synthesizing whole length BsAbs …
application. However, huge challenges still remain in synthesizing whole length BsAbs …
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
H Zong, X Li, L Han, L Wang, J Liu, Y Yue… - Acta Pharmacologica …, 2024 - nature.com
Antibody drug conjugate (ADC) therapy has become one of the most promising approaches
in cancer immunotherapy. Bispecific targeting could enhance the efficacy and safety of ADC …
in cancer immunotherapy. Bispecific targeting could enhance the efficacy and safety of ADC …
[HTML][HTML] A novel bispecific antibody targeting CD3 and Lewis Y with potent therapeutic efficacy against gastric cancer
J Chen, Z Pan, L Han, Y Zhou, H Zong, L Wang, R Sun… - Biomedicines, 2021 - mdpi.com
Lewis Y antigen, a glycan highly expressed on most epithelial cancers, was targeted for
cancer treatment but lacked satisfactory results in some intractable and refractory cancers …
cancer treatment but lacked satisfactory results in some intractable and refractory cancers …
[HTML][HTML] A rational designed novel bispecific antibody for the treatment of GBM
R Sun, Y Zhou, L Han, Z Pan, J Chen, H Zong, Y Bian… - Biomedicines, 2021 - mdpi.com
Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in
a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for …
a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for …
An anti-apoptotic HEK293 cell line provides a robust and high titer platform for transient protein expression in bioreactors
TA Arena, B Chou, PD Harms, AW Wong - MAbs, 2019 - Taylor & Francis
ABSTRACT HEK293 transient expression systems are used to quickly generate proteins for
research and pre-clinical studies. With the aim of engineering a high-producing host that …
research and pre-clinical studies. With the aim of engineering a high-producing host that …
[HTML][HTML] Development of a recombinant human IL-15· sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 …
M Zhao, M Luo, Y Xie, H Jiang, C Cagliero, N Li… - Biomedicine & …, 2019 - Elsevier
Abstract Recombinant human interleukin-15 (IL-15) is a potent cancer immunotherapeutic
candidate due to its excellent immune stimulating effects. Previous work demonstrated that …
candidate due to its excellent immune stimulating effects. Previous work demonstrated that …
[HTML][HTML] IgG-like bispecific antibody CD3× EpCAM generated by split intein against colorectal cancer
L Wang, Y Qiao, H Zong, L Han, Y Ke… - Frontiers in …, 2022 - frontiersin.org
Background: Colorectal cancer is a commonly diagnosed cancer with high mortality
worldwide. Postoperative recidivation and metastasis still are the main challenges in clinical …
worldwide. Postoperative recidivation and metastasis still are the main challenges in clinical …
Bioprocess development of a stable FUT8−/−-CHO cell line to produce defucosylated anti-HER2 antibody
Y Yuan, H Zong, J Bai, L Han, L Wang, X Zhang… - Bioprocess and …, 2019 - Springer
In recent years, an increasing number of defucosylated therapeutic antibodies have been
applied in clinical practices due to their better efficacy compared to fucosylated counterparts …
applied in clinical practices due to their better efficacy compared to fucosylated counterparts …